Perspective Therapeutics Inc

CATX remains in a high-confidence Stage 4 decline, trading below all major moving averages with no active patterns to support a rally. Medium-term bearish structure is intact under a sequence of lower highs and lower lows, and short-term conditions show a lack of upside follow-through into declining EMAs. Execution should focus on selling into any relief rallies around the 9/21 EMA zone. A decisive close and hold above those EMAs would invalidate the bearish bias.

• ↑Dosed first patient with [212Pb]VMT-α-NET in Phase 1/2a meningioma trial
• ↑High institutional interest via strong 13F ownership signals hedge fund confidence
• ↓Earnings yield of -3.57% indicates unprofitable operations